Mymetics Corp (MYMX)

[Work Harder]

Structure-Activity-Based Design of a Synthetic Malaria Peptide Eliciting Sporozoite Inhibitory Antibodies in a Virosomal Formulation

Shinji Okitsu

23.96EMD Serono Research and Development Institute

https://www.researchgate.net/publication/6307911_Structure-Activity-Based_Design_of_a_Synthetic_Malaria_Peptide_Eliciting_Sporozoite_Inhibitory_Antibodies_in_a_Virosomal_Formulation

Ursula Kienzl Head Hospital Sandoz Pharmaceuticals AG

Parent organization: Novartis

Rinaldo Zurbriggen & Gerd Pluschke

https://patents.justia.com/inventor/gerd-pluschke

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157159942

Anokion Secures $37.5 Million, Big Names Invest

https://drug-dev.com/anokion-secures-37-5-million-big-names-invest/

André J. Mueller

Mr.Mueller is Chairman of Addex Therapeutics, and a member of the Board of Sensimed SA. His earlier career includes positions with CIBA and SANDOZ

https://biography.omicsonline.org/switzerland/anokion/andr-j-mueller-64422

Someone jerking you around SP1 ?

Something to the Svlps ?

Check out Gerd Pluschke's patents

Develope rAnergis; Mymetics Corporation

https://adisinsight.springer.com/drugs/800037183